Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v25-EN | Version v14-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2022-05-01 | 2021-05-28 |
| Drug Identification Number | 02139499 | 02139499 |
| Brand name | MAGNESIUM SULFATE INJECTION | MAGNESIUM SULFATE INJECTION |
| Common or Proper name | Magnesium Sulfate Injection 500 mg/mL SD Vial 10 mL | Magnesium Sulfate Injection 500 mg/mL SD Vial 10 mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | MAGNESIUM SULFATE | MAGNESIUM SULFATE |
| Strength(s) | 500MG | 500MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS |
| Packaging size | 10 mL | 10 mL |
| ATC code | B05XA | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2021-04-01 | 2021-04-01 |
| Actual start date | 2021-04-01 | 2021-04-01 |
| Estimated end date | 2022-04-30 | Unknown |
| Actual end date | 2022-04-30 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | On 100% Allocation effective October 13, 2021. | Fresenius Kabi Canada Ltd. is pleased to advise that effective June 1, 2021, the allocation on our Magnesium Sulfate Injection 500 mg/mL SD Vial 10 mL will be increased to cover 100% of historical 10mL demand plus 25% of historical 50mL demand (on a 5:1 conversion ratio). |
| Health Canada comments |